Zhengye Biotechnology Holding Ltd (ZYBT) — SEC Filings
Zhengye Biotechnology Holding Ltd (ZYBT) — 7 SEC filings. Latest: 6-K (Dec 12, 2025). Includes 6 6-K, 1 20-F.
View Zhengye Biotechnology Holding Ltd on SEC EDGAR
Overview
Zhengye Biotechnology Holding Ltd (ZYBT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 20-F filed on Jul 3, 2025: Zhengye Biotechnology Holding Ltd (ZYBT) filed its 20-F for the fiscal year ended December 31, 2024, indicating its status as an annual report. The company, incorporated in the Cayman Islands, operates in the pharmaceutical preparations industry. As of December 31, 2024, Zhengye Biotechnology had an
Sentiment Summary
Across 7 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 4 neutral. The dominant filing sentiment for Zhengye Biotechnology Holding Ltd is neutral.
Filing Type Overview
Zhengye Biotechnology Holding Ltd (ZYBT) has filed 6 6-K, 1 20-F with the SEC between Jan 2025 to Dec 2025.
Recent SEC Filings (7)
| Date | Form | Description | Risk |
|---|---|---|---|
| Dec 12, 2025 | 6-K | 6-K Filing | |
| Jul 3, 2025 | 20-F | Zhengye Biotechnology Files 20-F, Confirms 45.6M Shares Outstanding | medium |
| May 23, 2025 | 6-K | Zhengye Biotech Receives NASDAQ Delinquency Notice | medium |
| Apr 3, 2025 | 6-K | Zhengye Biotechnology Forms New Company via Capital Contribution | low |
| Mar 6, 2025 | 6-K | Zhengye Biotechnology Appoints Aiden Han as Co-CEO | low |
| Jan 14, 2025 | 6-K | Zhengye Biotech IPO: Underwriters Exercise Full Over-Allotment Option | low |
| Jan 8, 2025 | 6-K | Zhengye Biotechnology Closes IPO | medium |
Risk Profile
Risk Assessment: Of ZYBT's 6 recent filings, 0 were flagged as high-risk, 3 as medium-risk, and 3 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Songlin Song
- Mr. Aiden Han
Industry Context
Zhengye Biotechnology Holding Ltd operates within the pharmaceutical preparations industry. This sector is characterized by significant research and development investment, stringent regulatory oversight, and a competitive landscape driven by innovation and market access. Companies in this industry often focus on developing, manufacturing, and marketing a range of pharmaceutical products.
Top Tags
biotechnology (2) · ipo (2) · 20-F (1) · Annual Report (1) · Pharmaceuticals (1) · SEC Filing (1) · Share Count (1) · Corporate Governance (1) · China (1) · delinquency-notice (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Ordinary Shares Outstanding | 45,666,376 | As of December 31, 2024, indicating the total number of shares in circulation. |
| Par Value per Share | $0.000025 | The nominal value assigned to each ordinary share. |
| Conformed Period of Report | 20241231 | The fiscal year-end covered by this annual report. |
| Commission File Number | 001-42450 | The SEC file number for Zhengye Biotechnology Holding Ltd. |
| Additional Shares | 225,000 | Purchased by underwriters due to full exercise of over-allotment option. |
| Share Price | US$4.00 | The price at which the additional shares were purchased. |
| Ordinary Shares Sold | 1,500,000 | Represents the total number of shares offered and sold in the IPO. |
| Par Value Per Share | $0.000025 | The nominal value assigned to each ordinary share. |
Frequently Asked Questions
What are the latest SEC filings for Zhengye Biotechnology Holding Ltd (ZYBT)?
Zhengye Biotechnology Holding Ltd has 7 recent SEC filings from Jan 2025 to Dec 2025, including 6 6-K, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ZYBT filings?
Across 7 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 4 neutral. The dominant sentiment is neutral.
Where can I find Zhengye Biotechnology Holding Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Zhengye Biotechnology Holding Ltd (ZYBT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Zhengye Biotechnology Holding Ltd?
Financial highlights for Zhengye Biotechnology Holding Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for ZYBT?
The investment thesis for ZYBT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Zhengye Biotechnology Holding Ltd?
Key executives identified across Zhengye Biotechnology Holding Ltd's filings include Songlin Song, Mr. Aiden Han.
What are the main risk factors for Zhengye Biotechnology Holding Ltd stock?
Of ZYBT's 6 assessed filings, 0 were flagged high-risk, 3 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Zhengye Biotechnology Holding Ltd?
Forward guidance and predictions for Zhengye Biotechnology Holding Ltd are extracted from SEC filings as they are enriched.